Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets
IFCT-1904
Phase 2 small_molecule active
Quick answer
Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets for BRAFV600E-mutant metastatic Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CERO THERAPEUTICS HOLDINGS, INC.
- Indication
- BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active